Team

Management

 

Marc Lemonnier

 Ph.D.,co-founder, CEO, is an entrepreneurial scientist with a deep knowledge of pathogenic bacterial infections and their biology. Marc holds a PhD in Microbiology from the University of Toulouse (France). He has carried out his research and bioentrepreneurial activities in an international context from Toulouse to New York City and has worked for and managed collaborations with major research institutions in Europe and the US (French CNRS and INSERM, CSIC Spain, Emory University in Atlanta GA). Marc is the author of numerous peer-reviewed articles in the antibacterial field and the inventor of ANTABIO’s technology.

Aymeric Dugray

Ph.D., co-founder, CFO, has both a business and scientific background. He has a Specialized Master of Entrepreneurship from ESCP-Europe. After co-founding and acting as CEO of Nokad®, a biotech CRO, he became the COO of Wittycell, a biotech company focused on the development of innovative vaccine adjuvants. He created and led two biotech specific entities that enabled young start-ups to share their employees and their professional networks. During these years, Aymeric has acquired expertise in the creation and management of innovative projects in the field of Biotechnology.

Delphine Ortega

MBA, International project manager & Business Developer, has both a scientific and business background (Biotech Engineer & Master of Global Innovation Management). Before joining ANTABIO, Delphine worked as a project manager at Neuroservice, a french CRO specialized in CNS safety, and later as a San Francisco-based Biotech Trade Advisor for Ubifrance, the French Agency for International Business Development. Delphine was responsible for organizing and managing multiple international partnering events involving biopharmaceutical companies of both sides of the Atlantic, from small start-up companies and bio-clusters to the top 10 players in the pharmaceutical industry.

Research & Development

David Davies

Ph.D., Head of Drug Discovery, has over 25 years of experience in medicinal chemistry within the pharmaceutical industry (GSK), most of which were dedicated to the development of antibiotic drugs for clinical use and biodefense. David has also worked with biotech companies in support of their strategy and medicinal chemistry efforts. He is an inventor on about 25 patents, most of them in the antibacterial area.  His antibacterial projects were supported by the Welcome Trust and the DTRA (US Defense Threat Reduction Agency).

Jérôme Castandet

Dr Jérôme Castandet
Ph.D., is a biologist with extensive experience in antibacterial drug discovery, from assay development to lead optimization. As the leader of a microbiology team in the Department of Infectious Diseases at Sanofi-Aventis R&D (Toulouse/Labège, France), Jérôme managed the in vitro biology aspects of different antibacterial discovery programs. Jérôme holds a PhD in Microbiology from the University of Toulouse and is the author of several peer-reviewed publications in the area of microbiology and immunology.

Alicia  Coelho

Ph.D., microbiologist, has dedicated her career to research on clinical multidrug-resistant pathogens and nosocomial infections. Alicia worked in the Microbiology research team of the Vall d’Hebron University Hospital in Barcelona (Spain) where she developed expertise in antimicrobial resistance, clinical diagnostic and bacterial genetics. Alicia holds a PhD in Microbiology from the Autonomous University of Barcelona and is the author of several scientific publications in the area of clinical microbiology and antimicrobial chemotherapy.

Laure Dedieu

Biology technician, Laure holds a Master in bioengineering and molecular and cellular technologies applied to health from the University of Toulouse.  She brings to ANTABIO her expertise in the fields of pharmacology and high-throughput screening, acquired in two major pharmaceutical companies: Sanofi-Aventis and Pierre Fabre.

Board

Jean-Loup Romet-Lemonne

M.D., non-executive Chairman, is the Program Director at IUIS (International Union of Immunological Societies), and former President and CEO of BioBusiness.TV, first independent internet-TV channel focused on the Life Science Industry. He is the founder of IDM Pharma Inc. (formerly NASDAQ: IDMI now part of Takeda Oncology) a developer of anti-cancer immunotherapy drugs and vaccines. Jean-Loup is also a former senior scientist from the Cancer Biology Department at Harvard School of Public Health, Boston, and associate professor at the Medical School of Tours University, France.

Helmuth Van Es

Ph.D.,  is managing director of BioConsilium, a strategic consultancy company for life sciences companies.  Helmuth is co-founder of Galapagos (1998) a global drug discovery company. As part of the business development team of Galapagos, he negotiated and established multimillion dollar alliances with GSK, Bayer, Incyte, Pharmacia and Boehringer-Ingelheim. Helmuth is also co-founder of drug-discovery companies Audion Therapeutics (2008) and Effecta Pharma (2009) and member of the Advisory Board of Spinnovation a high tech analytical NMR company.

Geoff Lawton

Ph.D., former Head of Medicinal Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. Geoff is the co-inventor of Cilazapril ®, a marketed drug. He has extensive experience in drug discovery and provides advice to a number of small companies. He was the founding Research Director with Lectus Therapeutics. He is a founder of INMedD, a new medicine discovery social enterprise. He also serves on the Scientific Advisory Board of Peakdale Molecular and advised Prolysis, a british antibacterial company recently acquired by the Australian company Biota.

Administration

Eudeline Mangini

Eudeline holds an HND Trilingual Executive Assistant from The University of Toulouse. She  brings to ANTABIO her expertise in administrative and logistical support at the international level, acquired during her past work experience at Egide, France’s leading agency in international mobility and key partner of the French Ministry of Foreign Affairs.